Novavax
Innovative Vaccine Developer
Pfizer
Pharmaceutical R&D Developer
1Month20On [date], Reuters reported that vaccine manufacturer Novavax (Novavax) announced on Tuesday that it has reached an agreement with Pfizer (Pfizer) Sign an authorization agreement related to vaccine development. Affected by this news, Novavax's stock price rose in pre-market trading.7%。
According to the terms of the agreement, Pfizer will obtain Novavax'sMatrix-MThe right to use the adjuvant. The role of the adjuvant is to enhance the immune response effect of the vaccine. Pfizer will have control over all research and development, production, and commercialization-related matters for products containing this adjuvant, with only the distribution and supply aspects of the products being outside its control.
In terms of transaction consideration, Novavax will2026Obtained in the first quarter of the year3000Million USD upfront payment. Meanwhile, the company is also eligible to obtain up to5Milestone payment of USD billion.
The achievement of this cooperation comes at a time when Novavax is facing multiple operational pressures. The company's COVID-19 vaccineNuvaxovidThe prescription volume has declined due to the U.S. issuing new COVID-19 vaccination recommendations, and weak vaccine sales have also sparked investor dissatisfaction.
Last year11Month, Novavax's second largest shareholder——Hedge FundShah CapitalPublicly pressuring the company's board of directors. The fund called on the board to advance strategic adjustments, including a potential sale, and warned that if there is no progress within the next four months, it will initiate a proxy fight.
Financial data shows that as of2025Year9Month30As of the day, Novavax's cash and cash equivalents were7.78billion dollars. This value is2024Year12Month31Day's9.38Billion US dollars has decreased.
In addition,1.26The impact of USD billion in non-cash expenses, the company2025Net loss widened in the third quarter of the year2.02billion dollars. The net loss for the same period last year was1.21Billion US dollars.
